Index

A
Abciximab, 46, 65–66
Accelerated idioventricular rhythm (AVIR), 190–191
Achalasia, 257–258
Acute coronary syndromes (ACS). See also Angina, unstable; Myocardial infarction, acute
cocaine-related, 205
definition of, 9, 60
diagnosis of, 61, 73–75. See also PAIN pathway, for acute coronary syndromes management
diagnostic tests for, 48, 303
initial assessment in, 37–38
missed, 303
emergency department evaluation of, 37–44
cardiac biomarkers in, 40–44
physical examination in, 39
epidemiology of, 25–26
ischemic cascade in, 97, 98
mechanisms of, 29–30
misdiagnosis of, 216
as mortality cause, 9, 220–221
racial differences in, 236
pathophysiology of, 26–32, 60
gender differences in, 221
prevalence of, 25–26, 73
primary prevention of, 302
symptoms of, 38
treatment of. See also PAIN pathway, for acute coronary syndromes management
age and gender differences in, 215–220
in the emergency department, 44–46
evidence-based, 9
future strategies in, 5–6
guidelines for, 9
during pre-coronary care unit era, 1–2
Adenosine
as heart block and syncope treatment, 1
as supraventricular tachycardia treatment, 183, 184
Adenosine diphosphate receptor antagonists, 65
Adhesion molecules, 27–28
Admission notes, for acute coronary syndrome patients, 20–24
African Americans
acute coronary syndrome in, 229–245
barriers to treatment of, 237–240
clinical presentation of, 236–237
endothelial dysfunction in, 234
risk factors for, 230–233
congestive heart failure treatment in, 129
C-reactive protein in, 233
diabetes mellitus in, 231
response to antithrombotic therapy, 235–236
Agency for Health Care Policy and Research (AHCPR), 63
Albumin cobalt binding test, 303
Aldosterone antagonists, 129, 195
American College of Cardiology/American Heart Association (ACC/AHA) guidelines
for acute coronary syndrome treatment, 20, 215–216
for calcium channel blocker use, 269
for chest pain evaluation, 62
for cocaine-related chest pain treatment, 208
for congestive heart failure treatment, 119
for electrocardiography, 40, 62
for hypertension management, 265
for non-ST segment elevation myocardial infarction treatment, 64, 65, 66
for paroxysmal supraventricular tachyarrhythmia treatment, 183
for secondary prevention in cardiovascular disease, 287
for ST-segment elevation myocardial infarction treatment, 48–49, 140
American Diabetes Association, 272, 273
Amiodarone
as atrial fibrillation treatment, 186
as shock-refractory ventricular fibrillation treatment, 192
as sudden cardiac death prophylaxis, 196
Amlodipine, 269, 290
Amrinone, use in cardiogenic shock patients, 139
Aneurysms, cardiac, 115–118
atrial, 115
pseudo, 115, 116, 117, 118
ture, 115, 116, 117, 118
ventricular, 101, 104, 108, 115
Angina pectoris
cocaine-related, 204
non-ST segment elevation myocardial infarction-related, 61–62
Prinzmetal (variant), 29, 30, 248
relationship to myocardial ischemia, 86
stable, 73
atherosclerotic plaque rupture in, 30
destabilization of, 3
symptoms of, 61
unstable, 73–85
anti-ischemic therapy for, 80–81
antiplatelet/antithrombotic therapy for, 78–80
classification of, 73
diagnosis of, 73–75
eyearly invasive versus conservative approaches to, 5, 219–220
in elderly patients, 220
evidence-based approach to, 68–69
medical therapy for, 66, 67
outcome estimation in, 63
outcome in, 221
pathophysiology of, 3
relationship to non-ST segment elevation myocardial infarction, 5, 60
risk stratification of, 75–76
treatment of, 76–81
in women, 219–220, 221
Angiography, coronary, 76, 154
of normal coronary arteries, 246
persistent chest pain during, 158
racial disparity in, 237–238
Angioplasty
facilitated, 54
primary
anatomic risk stratification strategy in, 52
arterial reocclusion after, 52
as cardiogenic shock treatment, 140
comparison with fibrinolytic therapy, 217–218
delayed, 55
door-to-balloon time in, 13, 53
in elderly patients, 217–218
first performance of, 4
“open artery hypothesis” of, 55
as reperfusion method, 48–49, 51–54
as ST-segment-elevation myocardial infarction treatment, 54, 55
in women, 217–218
rescue (salvage), 54–55
restenosis after, 4
Angiotensin-converting enzyme inhibitors (ACEI), 46
African Americans’ responses to, 234
contraindications to, 138, 269
therapeutic applications of acute coronary syndrome, 67
acute myocardial infarction, 269
congestive heart failure, 129
non-ST segment elevation
myocardial infarction, 67
unstable angina, 81
ventricular arrhythmia, 193–194
Angiotensin receptor blockers, 129
Anistreplase, contraindications to, 51
Antiarrhythmic drugs, type I, 195
contraindication in cocaine users, 206
Anticoagulation therapy, 2
for atrial fibrillation, 186
contraindication in aortic dissection, 256
discontinuation in pericardial effusion, 148, 149
for pulmonary embolism, 260–261
Antihypertensive therapy, 264–271, 290, 291
clinical considerations in, 265
pathophysiological basis for, 264–265
Antiplatelet therapy, 45
hemorrhage as contraindication to, 39
in high-risk patients, 302
therapeutic applications of acute myocardial infarction, 139
with catheter-based reperfusion strategies, 4
non-ST-segment elevation myocardial infarction, 65–66
supraventricular tachyarrhythmia, 182
unstable angina, 78–80
Antithrombotic therapy, 46
in elderly patients, 216
hemorrhage as contraindication to, 39
as hemorrhage cause, 216
racial differences in response to, 235–236
therapeutic applications of non-ST segment elevation myocardial infarction, 66–67
supraventricular tachyarrhythmia, 182
unstable angina, 78–80
in women, 216
Anxiety, ischemia-related, 81
Aorta, cocaine-related rupture of, 206–207
Aortic dissection
acute, diagnostic tests for, 48
ascending, 256–257
as chest pain cause, 11, 37, 256, 257
classification of, 256, 257
cocaine-related, 206–207
as contraindication to fibrinolytic therapy, 50
pericardial effusion associated with, 102
Aortic regurgitation, aortic dissection-related, 256
Aortic stenosis, as chest pain cause, 11, 252
Aortic valve disease, as chest pain cause, 252
Arrhythmias. See also specific types of arrhythmias
fatal, 25
myocardial infarction-related, 2
treatment of, during pre-coronary care unit era, 1–2
ventricular free wall rupture-related, 148
Arteries. See also specific arteries
non-coronary, atherosclerotic plaque detection in, 303
Aspirin
allergy to, 65
antiplatelet effects of, 3–4, 45
as cardiovascular disease prophylaxis, 302
contraindications to, 65
as myocardial infarction treatment, 139
in cocaine-related myocardial infarction, 208
in non-ST segment elevation myocardial infarction, 65, 78–79
in unstable angina, 78–79
Atenolol, 267
as atrial fibrillation treatment, 185
Atherosclerosis
as mortality cause, 25
pathophysiology of, 26–32
Atherosclerotic plaques
composition of, 60
echolucent carotid, 303
erosion of, 29, 32
Atherosclerotic plaques (cont.)
inflammatory cells in, 31, 32
in non-coronary arteries, 303
progression of, 26
rupture of, 26
as acute coronary syndrome cause, 29, 30
as myocardial infarction cause, 3
role of inflammation in, 27–29, 31, 32
“silent,” 32
statins-related prevention of, 81
as thrombosis cause, 26
triggers for, 32
as unstable angina cause, 3
underneath thrombi, 32
“vulnerable,” 26–27, 30–31
imaging detection of, 303
matrix disintegration theory of, 31
Atorvastatin, 81, 288, 289, 290
Atrial arrhythmias, atrial ischemia-related, 177
Atrial fibrillation, 180
complications of, 183
definition of, 179
ECG definitions of, 179, 180
treatment of, 183–186, 269
Atrial flutter
complications of, 183
definition of, 179
ECG definitions of, 179–180
treatment of, 183–186, 269
Atrial systole, 253
Atrial tachyarrhythmias
acute myocardial infarction-related, 175
definition of, 175
ST-segment elevation myocardial infarction-related, 182–184
types and ECG definitions of, 178–181
Atrial tachycardia
adenosine treatment of, 184
multifocal, 179
unifocal, 178–179
Atrioventricular block
atrial ischemia-related, 177
bifascicular block, 172
as bradyarrhythmia cause, 165
first-degree, 168–169
intraventricular block, 171–172
second-degree, 169
Mobitz type I (Wenckebach), 169
Mobitz type II, 169–170
third-degree (complete heart block), 167, 168, 170–171
trifascicular, 169–170
Atrioventricular junctional tachycardia, nonparoxysmal, 180–181
Atrioventricular nodal artery, 177
Atrioventricular nodal reentrant tachycardia, adenosine treatment of, 184
Atrioventricular node
anatomy of, 163, 164
blood supply to, 164
junctional bradycardia of, 167
sub subsidiary cardiac pacemaker function of, 166
Atrioventricular reentrant tachycardia, adenosine treatment of, 184
Atropine, as coronary spasm treatment, 2
Azimilide, 196
B
Bed rest, as acute myocardial infarction treatment, 1, 2
Benzodiazepines, as cocaine-related myocardial infarction treatment, 208
Beta-adrenoreceptor blockade, 3
Beta-blockers, 45
action mechanism of, 80
antiarrhythmic effects of, 267
antihypertensive effects of, 267–268
anti-ischemic effects of, 267
contraindications to, 268
cardiogenic shock, 138
coronary artery spasm, 249
junctional bradycardia, 167
myocarditis, 256
sinus bradycardia, 167
ST-segment elevation myocardial infarction, 185
therapeutic applications of acute coronary syndrome, 80, 267–268
cocaine-related myocardial infarction, 208
in combination with calcium channel blockers, 269
congestive heart failure, 126–128, 129
myocardial bridging, 250
non-ST-segment elevation myocardial infarction, 64
unstable angina, 80
ventricular arrhythmia, 193
ventricular tachycardia prophylaxis, 193
Bezold-Jarisch cardioinhibitory reflex, 166
Biomarkers, cardiac, 37, 38, 40–44
assays of, 41
definition of, 40, 62
in myocardial necrosis, 62
novel, 303
in ST-segment-elevation myocardial infarction, 55–56
Biopsy, endomyocardial, 124
Bivalirudin, 218
Blood pressure
diastolic, excessively low, 265
normal, 290
as prehypertension, 290
systolic, 265
as cardiovascular disease predictor, 230
Boerhaave syndrome, 257–258
Bone marrow infusion therapy, 304
Bradyarrhythmias, acute myocardial infarction-related, 163–174
asymptomatic, 172
atrioventricular block, 163
conduction-related, 163, 166, 168–172
definition of, 163
diagnosis of, 163
pacemaker-related, 166–168
idioventricular rhythm, 166, 168
junctional bradycardia, 166, 167
sinus bradycardia, 166–167
pathophysiology of, 163–166
sinus bradycardia, 163
B-type natriuretic peptide (BNP), 43
Bundle branch
left
anatomy of, 164
block of, 40, 171, 172
blood supply to, 165
right
anatomy of, 164
block of, 171, 172
blood supply to, 165
Bupropion, 298–299
C
Calcium channel blockers, 268–269
contraindications to, 167, 269
dihydropyridine, 268, 269
non-dihydropyridine, 268
therapeutic applications of cocaine-related myocardial infarction, 208
coronary artery spasm, 249
non-ST segment elevation myocardial infarction, 64
unstable angina, 80–81
Canadian Cardiovascular Society, Angina Grading System of, 73, 74
Captopril, 46
as sudden cardiac death prophylaxis, 198
Carbohydrates, dietary intake of, 292
Cardiac care units (CCUs)
development of, 2
mobile, 2
percentage of diabetic patients in, 273
percentage of glucose-intolerant patients in, 273
priority myocardial infarction treatment in, 14
Cardiac output, in acute coronary syndrome, 181
Cardiologists, as acute coronary syndrome treatment providers, 216
Cardiomyopathy, 251–252
chest pain associated with, 11, 251–252
cocaine-related, 204, 207, 208–209
dilated, 251
hypertrophic, 11, 252
ischemic, 198
nonischemic, 251
stress (Takotsubo), 207, 252
Cardiovascular disease. See also specific types of cardiovascular disease
with coronary microvascular dysfunction, 250–251
as mortality cause, 212
primary prevention in, 287
secondary prevention in, 5, 286–294
Cardiovascular disease (cont.)
algorithm for, 286–287
with statin therapy, 302
in women, atypical presentation of,
214
Cardioversion
direct current electrical, 183, 184–185
pharmacological, 184
Carvedilol, 193
as congestive heart failure treatment,
128
Catheterization, cardiac
anatomic risk stratification strategy in,
44, 52
for cardiogenic shock evaluation,
137–138
coronary, first performance of, 4
early, in women, 219–220
in elderly patients, 218
for heart failure evaluation, 124
for interventricular septal rupture
evaluation, 111–112
left heart, 138
for papillary muscle rupture
evaluation, 114
pulmonary artery, in decompensated
heart failure, 121
right heart, 138
in women, 218, 219–220
Chemoattractant molecules, in
atherogenesis, 28
Chest pain. See also Angina pectoris
cocaine-related, 204–211
during coronary angiography, 158
echocardiographic evaluation of,
104–106
emergency department evaluation of,
37–44, 104–106
life-threatening causes of, 37, 38
non-life-threatening, non-cardiac
causes of, 11, 38
with normal coronary arteries,
246–247
of coronary origin, 246–247, 248–253
economic impact of, 248
epidemiology of, 247
of non-coronary origin, 246, 247,
253–261
pericardial, 145–147
racial differences in, 234, 236
in women, 213
“Chest pain centers,” 104–105
“Chest pain pathway.” See PAIN
pathway, for acute coronary
syndromes management
Cholesteryl ester transfer protein, 302
Clopidogrel, 45, 65, 78–79, 302
Coagulation studies, 41
Cocaine
as aortic dissection risk factor, 256
as atherosclerotic plaque rupture risk
factor, 32
cardiovascular effects of, 205–209
pharmacology and action mechanisms
of, 204–205
Columbia University, College of
Physicians and Surgeons, 9, 20–24
Computed tomography
of aortic dissection, 257
spiral, of pulmonary embolism, 260
Computed tomography angiography,
multislice, 303
Conduction system, cardiac
anatomy and function of, 163–164
blood supply of, 164–165
impulse propagation failure in, 163,
168–172
Congestive heart failure, 119–131
acute decompensated, 119–131
bedside assessment of, 124–125
diagnosis, 121–125
natriuretic peptide assays of,
121–123
new-onset versus acute exacerbation
of, 123–124
treatment of, 125–129, 270
chronic, exacerbation of, 123–124
in elderly patients, 214–215
non-ST-segment elevation myocardial
infarction-related, 67–68
supraventricular tachycardia-related,
175
treatment of
angioplasty versus fibrinolytic
treatment, 52–53
with angiotensin-converting enzyme
inhibitors, 269
with beta-blockers, 193
guidelines for, 119
with nitrates, 63
in women, 214
Coronary arteries
dissection of, aortic dissection-related, 256
normal, in chest pain, 246–247
of coronary origin, 246–247, 248–253
economic impact of, 248
epidemiology of, 247
of non-coronary origin, 246, 247, 253–261
right
in inferior myocardial infarction, 177
occlusion of, 165, 166
spasms of, 2, 64, 248–249
Coronary artery bypass grafting (CABG)
after primary angioplasty, 51
complications of, 219
in elderly patients, 219
myocardial protection during, 159
as non-ST-segment-elevation myocardial infarction treatment, 155, 156
as ST-segment-elevation myocardial infarction treatment, 140, 155, 157–158
urgent or emergent, 52
in women, 219
Coronary artery disease (CAD)
incidence of, 25
as mortality cause, 37
smoking-related, 296
in women, 212
Coronary calcium scanning, 87, 90, 94
Coronary heart disease
incidence of, 25
risk factors for, 212
in African Americans, 230–233
in Hispanics, 230, 231
in older adults, 212–213
in women, 212–213
C-reactive protein, 233
Creatine kinase
cocaine-related increase in, 206
in statin-related myopathy, 289
Creatine kinase-MB, 41–43, 55, 56, 62
cocaine-related increase in, 206
in noncardiac conditions, 43
Cytokines, inflammatory, 28–29

D
D-dimer, 260–261
Defibrillators. See Implantable cardioverter defibrillators
Diabetes mellitus
blood pressure levels in, 290
as cardiovascular disease risk factor, 272–273
in African Americans, 231–232, 234, 236
gender factors in, 213
in Hispanics, 231
as epidemic, 272
hyperglycemia management in, 276–283
hyperosmolar state in, 278
hypertension associated with, 236
ketoacidosis associated with, 278, 281
as myocardial infarction-related mortality risk factor, 272
in women, 212
Diet, cardioprotective, 288, 291–292
Digoxin, as atrial fibrillation treatment, 186
Diltiazem
as atrial fibrillation treatment, 185
contraindication in left ventricular dysfunction, 81
Discharge planning, 20–24
Diuretics
as congestive heart failure treatment, 125, 126, 129
thiazide, 291
Dobutamine
cardiogenic shock-related, 139
as congestive heart failure treatment, 128
Dobutamine stress echocardiography, 105
Dofetilide, 196
Dopamine, in cardiogenic shock, 139
Dressler’s syndrome, 147, 151
Dyslipidemia. See also Hypercholesterolemia
statin therapy for, 287–290
Dyspnea
  in older patients, 213
  in women, 213

E
Echocardiography, 96–107
  of cardiac aneurysms, 116, 117
  of cardiac tamponade, 150
  for cardiogenic shock evaluation, 137
  color flow Doppler, 97–98
  in the coronary care unit, 103–104
  in the emergency department, 104–106
  of interventricular septal rupture, 111, 112
  of left ventricular hypertrophy, 231
  of myocardial infarction, 97–99, 108
  of myocarditis, 255
  of papillary muscle rupture, 114
  of pericardial disease, 147
  of pericarditis, 254
  stress, 87, 88, 92, 94, 104–105
  transesophageal, 96–97
    of aortic dissection, 257
    for cardiogenic shock evaluation, 137
    in the coronary care unit, 103, 104
    intraoperative, 154
    of papillary muscle rupture, 101
    of pulmonary embolism, 260
    of ventricular free wall rupture, 149
      transthoracic, 96
        in the coronary care unit, 103, 104
        of left ventricular thrombus, 102
        of ventricular free wall rupture, 110, 149

Edema, pulmonary, 183

Elderly patients
  acute coronary syndrome in
    clinical signs and symptoms of, 214
    comorbid conditions in, 214–215
    mortality rate in, 221
    adverse drug effects in, 215
    aortic dissection in, 256
  Electrocardiography (ECG)
    of acute coronary syndromes, 37–38,
      39–40, 61, 62
    in elderly patients, 215
    for risk stratification, 62
    in women, 215
    of atrial infarction, 177–178
    of cocaine-related myocardial
      infarction, 206
    of pericardial disease, 147, 254
    12-lead, 40
      of ST-segment-elevation myocardial
        infarction, 48

  Electrophysiological studies
    of congestive heart failure, 128
    post-myocardial infarction, 197, 198–199
  Embolism, pulmonary
    as chest pain cause, 11, 37, 259–261
    diagnosis of, 259–260
    differentiated from aortic dissection, 256
    as myocardial infarction complication, 2
    treatment of, 260–261

  Emergency departments
    acute coronary syndromes evaluation
      in, 37–44
    acute coronary syndromes treatment
      in, 44–46
    echocardiography use in, 104–106
  Enalapril, 269, 290
  Encainide, 195
  Endocarditis, cocaine-related, 207
  Endothelium, vascular
    atheroprotective function of, 27
    desquamation of, 29
    dysfunction of, 249–250
    in African Americans, 234
    hyperglycemia-related, 274
    inflammation-related, 27–29
    microvascular, 253
  Enoxaparin, 79
  Eplerenone, 195
  Eptifibatide, 46, 65–66, 79–80
    racial differences in response to, 236
  Ergonovine maleate, 249
  Esmolol, 45, 185
  Esophageal disorders
    as chest pain cause, 257–258
    differentiated from aortic dissection, 256
    spasms, 257–258
    tears/ruptures, 48
  Estrogen, cardioprotective effects of, 221
  Estrogen deficiency, 213
European Society of Cardiology, 119
Exercise stress testing, 249, 251, 293

F
Fat, dietary, 292
Fibrinogen, 235
Fibrinolysis, racial differences in, 234–235
Fibrinolytic therapy
arterial reocclusion after, 52
for myocardial infarction
mortality rate in, 236–237
racial differences in response to, 236–237
for ST-segment elevation myocardial infarction
cardiac biomarker assessment of, 55–56
contraindications to, 50–51
versus reperfusion therapy, 49–50
timing of, 49, 50
Filters, inferior vena cava, 260–261
Flecanide, 195
Fluvastatin, 288, 289
Framingham Heart Study, 25
Framingham Risk Score, 213
Free wall rupture. See Ventricular free wall rupture
Friction rubs
pericardial, 147, 253–254
pleural, 253–254

G
Gastroesophageal reflux disease (GERD), 257–258
Genetic factors, in acute coronary syndrome, 302–303
Glucose intolerance, in cardiac care unit patients, 273
Glycoprotein IIb/IIIa inhibitors, 46
adjuvant use of, 4
administration prior to percutaneous interventions, 66, 67
in combination with facilitated angioplasty, 54
low-molecular-weight heparin, 79
as hemorrhage cause, 216
as myocardial infarction treatment, 139
in female or elderly patients, 216
in non-ST-segment elevation myocardial infarction, 65–66, 216
in ST-segment elevation myocardial infarction, 13
preoperative administration of, 154
as unstable angina treatment, 79–80, 216

H
Health care, racial disparities in, 237–238
Heart block, complete, 170–171
idioventricular rhythm in, 168
junctional bradycardia in, 167
Heart murmurs, papillary muscle rupture-related, 114
Heart rate
in acute coronary syndrome, 181
effect on myocardial oxygen demand, 264–265
Hemopericardium, 109, 149, 256
Hemorrhage
aortic dissection-related, 256
glycoprotein IIb/IIIa inhibitors-related, 80
intracranial, 50
percutaneous coronary interventions-related, 218
risk evaluation of, 39
thrombolytic therapy-related, 217
Hemostatic factors, racial differences in, 234–235
Heparin
as cardiogenic shock treatment, 139
low-molecular-weight, 46
as non-ST-segment elevation myocardial infarction treatment, 66–67
as unstable angina treatment, 79
preoperative administration of, 154
racial differences in response to, 236
unfractionated, 46, 66, 79
action mechanism of, 79
as acute coronary syndrome treatment, 216
as hemorrhage cause, 216
as non-ST-segment elevation myocardial infarction treatment, 66
as unstable angina treatment, 79
High-density lipoprotein (HDL) as acute coronary syndrome treatment, 302
cholesteryl ester transfer protein-related increase in, 302
high levels of, 302
in African Americans, 232
low levels of
gender differences in, 213
as metabolic syndrome component, 213, 231
treatment of, 288
Hirudin, racial differences in response to, 236
His bundle
anatomy of, 164
blood supply to, 164
in complete heart block, 170
Hispanics
acute coronary syndromes in, 229–245
C-reactive protein in, 233
diabetes mellitus in, 231
Hormone replacement therapy, 233
Hydralazine, contraindication to, 270
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, 194, 287–290
action mechanism of, 67, 81
as acute coronary syndromes prophylaxis, 302
as acute coronary syndromes treatment, 67, 302
contraindications to, 289
monitoring of, 289
as non-ST-segment elevation myocardial infarction treatment, 67
side effects of, 288
Hypercholesterolemia as ischemic heart disease risk factor, 230
in women, 212
Hyperglycemia
as acute coronary syndrome complication, 272–285
as cardiovascular disease risk factor, 272–273
in hospitalized cardiac patients, management of, 274–283
as hypoglycemia cause, 276, 280
pathway for, 276–283
metabolic effects of, 273–274
stress, 272, 273
Hypertension in African Americans, 230, 231–232, 236
as chest pain cause, 250–251, 259
as contraindication to thrombolytic therapy, 266
diabetes mellitus-associated, 236
endothelial dysfunction in, 234
left ventricular hypertrophy-related, 251
as metabolic syndrome component, 213, 231
prevalence of, 230
pulmonary, as chest pain cause, 259
treatment of
with diet and nutrition, 291
with pharmacotherapy, 264–271, 290, 291
uncontrolled, 51
in women, 212
Hypertensive emergency, 265, 270
Hypoglycemia, 276, 280
Hypoperfusion, cardiogenic shock-related, 132, 139
Hypotension
angiotensin-converting enzyme inhibitors-related, 81, 269
cardiac tamponade-related, 149
cardiogenic shock-related, 132, 136, 138–139
junctional bradycardia-related, 167
morphine-related, 81, 270
nitrates-related, 1
sinus bradycardia-related, 167
ventricular free wall rupture-related, 148
Hypothermia, therapeutic, 304
Hypoxia, 63
I
Idioventricular rhythms, 166, 168
Immunosuppression, hyperglycemia-related, 273–274
Implantable cardioverter defibrillators, 197–199
versus antiarrhythmic drug therapy, 194
Inflammation, in atherogenesis, 27–29, 31, 32
Insulin resistance, as metabolic syndrome component, 231
Insulin therapy, in hospitalized patients, 276–283
conversion to subcutaneous insulin, 281–283
Interferon-γ, 29, 31
Internal mammary arteries, 160
Interventricular septum, post-infarct rupture of, 110–112
Intraaortic balloon counterpulsation (IABP), 158–159
as cardiogenic shock treatment, 139
with off-pump surgery, 160
as ventricular free wall rupture treatment, 109, 110
Ischemia. See also Myocardial ischemia
aortic dissection-related, 256
atrial, 177
persistent refractory, 155
post-myocardial infarction, 97, 98
Ischemic cascade, 97, 98
Ischemic heart disease
antiarrhythmic drug therapy for, 195
left ventricular hypertrophy-related, 230
J
Jugular venous distention, 136
Junctional atrioventricular bradycardia, 167
Junctional tachycardia, nonparoxysmal, 183
K
Ketoacidosis, diabetic, 278, 281
Kussmaul’s sign, 138
L
Labetalol, 208
Left anterior descending artery, 109
Left atrial circumflex artery, 177
Left circumflex artery, 164, 177
as papillary muscle blood supply, 113
in ventricular free wall rupture, 109
Left ventricle
dysfunction of
antiarrhythmic drug therapy for, 193, 195, 196
as contraindication to diltiazem, 81
non-ST-segment elevation myocardial infarction-related, 67
supraventricular tachyarrhythmia-related, 181
hypertrophy of
in African Americans, 230–232
echocardiography of, 231
hypertension associated with, 251, 264
myocarditis-related, 255–256
rupture of, echocardiographic assessment of, 99–100
thrombi in, 101–102
Left ventricular assist devices, 139–140
Left ventricular failure, as cardiogenic shock cause, 134–135, 136, 138, 140
Leukocyte adhesion molecules, 28
Lidocaine
use in cocaine-using patients, 208
as ventricular arrhythmia prophylaxis, 192
Lifestyle modifications, 290, 302
Lipid-lowering drugs, 194, 302
Lipid profiles, of African Americans, 232–233
Lipoprotein (a), in African Americans, 232, 233
Lisinopril, 46, 234
Liver disease, as contraindication to statin therapy, 289
Liver failure, statin therapy-related, 288, 289
Lovastatin, 288, 290
Low-density lipoprotein (LDL), 288
small-particle, as metabolic syndrome component, 213
statin-related reduction in, 81
Low-fat diets, 292
M
Macrophage colony-stimulating factor, 28
Mallory-Weiss tears, 257–258
Marfan syndrome, 256
Matrix metalloproteases, 31
Mechanical assist devices, as cardiogenic shock treatment, 140
Medicare, 293
Mediterranean diet, 291–292
Metabolic syndrome, 213, 231, 288
Metoprolol
as acute myocardial infarction treatment, 267–268
as atrial fibrillation treatment, 185
as ventricular fibrillation treatment, 193
Microalbuminuria, in African Americans, 234
Microvascular dysfunction, coronary, 250–251, 252–253
Milrinone
as congestive heart failure treatment, 128
limitations to use of, 139
Mitrval regurgitation
as cardiogenic shock cause, 134, 136, 137
coronary artery bypass graft surgery for, 155
post-myocardial infarction, 102, 103
Mitral valve disease, as chest pain cause, 252
Moricizine, 195
Morphine, 1, 45, 270
hemodynamic effects of, 270
as unstable angina treatment, 81
Morphine sulfate, 64
Muscles, cardiac, 154
Myocardial bridging, 250
Myocardial infarction, acute
in African Americans, 232
barriers to treatment of, 237–239
age factors in, 212
anterior
biomarkers of, 43
interventricular septal rupture associated with, 110, 111
preshock syndrome of, 132–133
arrhythmias associated with atrial tachyarrhythmias, 175–176
as mortality cause, 2
atrial infarction associated with, 177–178
as cardiogenic shock cause, 132–143
cocaine-related, 204, 205–206
coronary artery plaque rupture-related, 29
differentiated from coronary spasm, 248
pericarditis, 145–147
incidence of, 25
infarct size limitation in, 3
inferior
interventricular septal rupture associated with, 110, 111
sinus bradycardia in, 166
with ventricular septal rupture, 100
inferoposterior, 165
as left ventricular dysfunction cause, 3
left ventricular hypertrophy-related, 230–231
mechanical complications of, 108–118
cardiac aneurysm and pseudoaneurysm, 108, 115–118
echocardiographic assessment of, 99–102
interventricular septum rupture, 110–112
papillary muscle rupture, 113–115
ventricular free wall rupture, 109–110
as mortality cause, 2, 272
gender differences in, 220–221
non-ST-segment elevation (NSTEMI) cardiogenic shock associated with, 133
congestive heart failure associated with, 67–68
diagnosis of, 61–62
early invasive versus early conservative approach to, 76–78, 219–220
early revascularization in, 67–68
in elderly patients, 220
emergency department treatment of, 37
evidence-based approach to, 68–69
with left ventricular dysfunction, 67
pathophysiology of, 3, 60–61
prognosis in, 68–69
racial differences in, 236
treatment of, 63–68
in women, 219–220
pathogenesis/pathophysiology of, 264
pericardial involvement in, 147–149
posterior, sinus bradycardia in, 166
recurrent, prevention of, 6, 66
reinfarction, 43
risk stratification of, 98
smoking-related, 296
ST-segment depression prior to, 40
ST-segment elevation (STEMI)
  anterior, 52
cardiac biomarkers of, 55–56
cardiac output in, 181
cardiogenic shock associated with,
  133, 140
diagnosis and treatment of, 48–59
early invasive versus conservative
  approaches to, 5
facilitated angioplasty of, 54
fibrinolytic versus reperfusion
  therapies for, 49–50
incidence of, 5
mechanical complications of, 49
“open artery hypothesis” of, 55
PAIN pathway protocol for, 12–14
pathophysiology of, 3
plasma glucose levels in, 272
primary angioplasty of, 4
racial differences in, 236
reperfusion therapy for, 48–49
rescue (salvage) angioplasty of,
  54–55
supraventricular tachyarrhythmia
  in, 181
thrombolytic therapy for, 3, 217
treatment algorithm for, 48
treatment guidelines for, 48–49, 140
ventricular free wall rupture in,
  148–149
supraventricular tachyarrhythmias
  associated with, 175
treatment of
  “armchair” treatment, 2
  bed rest as, 1, 2
during pre-coronary care unit era,
  1–2
ventricular arrhythmias after, 190–203
accelerated idioventricular rhythm,
  190–191
implantable cardioverter-
  defibrillators for, 197–199

lidocaine prophylaxis for, 192
medical therapy for, 193–196
nonsustained ventricular
tachycardia, 191
premature ventricular contractions,
  190
sustained ventricular tachycardia,
  191–192
therapeutic approach to, 192–199
ventricular fibrillation, 191–192
Myocardial infarction, old, coronary
  plaque rupture in, 25
Myocardial ischemia
cocaine-related, 208
evaluation of, 40
as myocardial damage cause, 3
pathophysiology/pathophysiology of,
  264
relationship to angina, 86
  “silent,” 86
Myocardial salvage, 304
Myocarditis, 254–256
  cocaine-related, 207, 208–209
subclinical, 255
Myocardium, ischemic, preservation
  strategy for, 304
Myoglobin, ischemic, preservation
  strategy for, 304
Myoglobin, as cardiac biomarker,
  43–44, 55, 56, 62
Myopathy, statins-related, 288, 289,
  290
MyPyramid.gov, 292

N
Natriuretic peptides, 43, 121–123
Neutropenia, azimilide-related, 196
Nicotine, 297. See also Smoking
Nicotine replacement therapy, 297–298
Nifedipine, 81, 268–269
Nitrates, 45
  action mechanism of, 80
  in combination with morphine, 81
  contraindication in cardiogenic shock,
    138
  as hypotension cause, 1
  therapeutic applications of
    cocaine-related myocardial
    infarction, 208
coronary artery spasms, 249
myocardial bridging, 250
Nitrates (cont.)
- unstable angina, 80
- therapeutic applications of non-ST segment elevation myocardial infarction, 63–64

Nitric oxide, 29
Nitroglycerin
- cardiovascular effects of, 267
- contraindications to, 139, 167, 267
- preoperative administration of, 154
- therapeutic applications of coronary spasm, 2
- hypertension, 267–268
- non-ST segment elevation myocardial infarction, 63–64
- unstable angina, 80
Nitroprusside, 270
Nonsteroidal anti-inflammatory drugs (NSAIDs)
- contraindication in myocarditis, 256
- as pericardial pain treatment, 254
- as ventricular free wall rupture risk factor, 109
Nuclear factor 5%, 29
Nurses, arrhythmia treatment by, 1, 2

O
Obesity, as metabolic syndrome component, 213, 231
Off-pump surgery, 159, 160
“Open artery hypothesis,” 55
Oral contraceptives, 213
Oxygen demand, myocardial, hypertension-related decrease in, 264–265
Oxygen therapy
- for acute myocardial infarction, 2
- for non-ST segment elevation myocardial infarction, 63
- for ST-segment-elevation myocardial infarction, 49
- for supraventricular tachyarrhythmia, 182

P
Pacemakers, biventricular, 128–129
PAIN pathway protocol, 9–19, 48, 86
- Advanced Risk, 9, 14–16, 37–38, 44
  goals of, 11–18
- as indication for cardiac catheterization, 44
- initial assessment in, 11
- Intermediate Risk, 9, 16–17, 37–38
  as indication for stress testing, 86–95
- Low or Negative Risk, 9, 17–18, 37–38, 44, 87
  as indication for stress testing, 86–95
- Priority Risk, 9, 12–14, 37–38
  for ST-segment elevation myocardial infarction, 12–14
Papaverine, as coronary spasm treatment, 2
Papillary muscle rupture, 137
diagnosis and management of, 113–115
echocardiographic assessment of, 101
as indication for mitral valve repair/replacement, 102
as mitral regurgitation cause, 101
right ventricular infarction-related, 100
Peptic ulcers
- as chest pain cause, 48, 257–258
- as contraindication to fibrinolytic therapy, 51
  perforated, 48
Percutaneous coronary interventions. See also Angioplasty
glycoprotein IIb/IIIa inhibitor therapy prior to, 66, 67
as hemorrhage cause, 218
transfer of patients for, 53–54
Pericardial constriction, 254
Pericardial disease, 144–153
Pericardial effusions, 11, 102, 147–149, 150, 254
Pericardiocentesis, as cardiac tamponade treatment, 149
Pericarditis
- acute, diagnostic tests for, 48
- as chest pain cause, 11, 253–254
differentiated from myocardial infarction, 145–147
infarction, 147–148
Pericardium
- anatomy of, 144, 253
  physiology of, 144–145
Phosphodiesterase inhibitors, 139, 267
Physical activity, cardioprotective effects of, 293
Pleurisy, as chest pain cause, 259
Pneumomediastinum, diagnostic tests for, 48
Pneumonia, as chest pain cause, 259
Pneumothorax
differentiated from aortic dissection, 256
tension, 48, 259
Post-myocardial infarction syndrome, 147, 151
Prasugrel, 302
Pravastatin, 288, 289, 290
Pregnancy
as aortic dissection risk factor, 256
as contraindication to fibrinolytic therapy, 51
Pregnancy-associated plasma protein A, 303
Prehypertension, 290
Premature atrial complexes, 178, 183
Premature ventricular arrhythmias, 193
Premature ventricular contractions, 190

Principles of Internal Medicine
(Harrison), 2
Pseudoaneurysm, ventricular, 101, 108
Pulmonary disorders, as chest pain cause, 256, 259–261
Pulsus paradoxus, 138
Purkinje fibers, anatomy and function of, 164

Q
Quinidine, 1

R
Rales, 2, 136–137
Rehabilitation, cardiac, 2, 293
Remodeling, cardiac, 103–104
Renal disease, blood pressure levels in, 290
Renal failure, aortic dissection-related, 256
Reperfusion injury, 157–158, 304
Reperfusion therapy, 4
for cardiogenic shock, 140
for ST-segment-elevation myocardial infarction, 48–49
cardiac biomarker assessment of, 55–56
versus fibrinolytic therapy, 49–50
versus primary angioplasty, 51–53
with primary angioplasty, 48–49, 51–54
time to, 238
Resistin, 303
Revascularization, 155–158. See also
Coronary artery bypass grafting (CABG)
early, versus conservative therapy, 5, 219–220
as non-ST-segment elevation myocardial infarction treatment, 67–68
as ST-segment elevation myocardial infarction treatment, 140
Risk stratification, cardiac, 37–38, 62–63. See also PAIN pathway, for acute coronary syndromes management
with electrocardiography, 39–40
with stress testing, 86–95
with computed tomography angiography, 87, 90, 93
with coronary calcium scanning, 87, 90, 94
of low-to-intermediate risk chest pain patients, 86–95
with SPECT imaging, 87, 88, 90, 92–93
with stress echocardiography, 87, 88, 92, 94
in unstable angina/non-ST-segment elevation myocardial infarction, 5
Rosuvastatin, 288, 289

S
St. Luke’s Roosevelt Hospital Center, 9, 20–24
Secondary prevention, in cardiovascular disease, 5, 286–294
algorithm for, 286–287
with statins, 302
Sedentary lifestyle, as coronary artery disease risk factor, 293
Shock, cardiogenic, 80, 132–143
diagnosis of, 136–137
echocardiographic evaluation of, 137
etiology of, 134–136
incidence of, 133
left ventricular, 134–135, 138
as mortality cause, 132
nonhypotensive, 132
preshock syndrome of, 132–133, 136
prognosis in, 140–141
right ventricular, 134, 136–137, 138
risk factors for, 133–134
supraventricular tachyarrhythmias-related, 175, 183
treatment of, 138–140
angioplasty versus medical treatment of, 52
with coronary artery bypass grafting, 155
with intraaortic balloon counterpulsation, 158
in women, 214
Simivasatin, 288, 289
Single-positron emission computed tomography (SPECT), in stress testing, 87, 88, 90, 92–93
Sinoatrial node
anatomy and function of, 163, 164
blood supply to, 164
in bradyarrhythmia, 165
cardiac pacemaker function of, 166
Sinoatrial node artery, 164, 166
Sinus bradycardia, 163
Sinus node, in junctional bradycardia, 167
Sinus node artery, 164, 177
Sinus tachycardia, 178
persistent, 183
ST-segment elevation myocardial infarction-related, 182–184
treatment of, 183
Smokers, atherosclerotic plaques in, 32
Smoking
cardiovascular effects of, 296–297
acute coronary syndromes, 212
in African Americans, 231–232
coronary spasm, 248
gender factors in, 213
ischemic heart disease, 230
myocardial infarction, 248
public ban on, 302
Smoking cessation, in cardiac disease patients, 295–301
Sotalol, 195–196
Spironolactone, effect on ventricular ectopy, 195
Statins. See 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
Stents
coronary, 76
arterial reocclusion rates of, 52
drug-eluting, 4
metallic, 4
Steroids, as ventricular free wall rupture risk factor, 109
Streptokinase
contraindications to, 51
as coronary thrombosis treatment, 3
Stress testing, 86–95
echocardiographic, 87, 88, 90, 92–93, 104–105
of low-to-intermediate risk chest pain patients
with computed tomography angiography, 87, 90, 93
with coronary calcium scanning, 87, 90, 94
imaging protocol selection for, 92
with SPECT imaging, 87, 88, 90, 92–93
with stress echocardiography, 87, 88, 92, 94
Stroke
aortic dissection-related, 256
as contraindication to fibrinolytic therapy, 50
left ventricular hypertrophy-related, 230–231
ST-segment depression, 40
cardiac ischemia/infarction-related, 62
ST-segment elevation. See also Myocardial infarction, acute, ST-segment elevation
cardiac ischemia/infarction-related, 62
in women, 215
Sudden cardiac death
acute coronary syndromes-related, 25
arrhythmias-related, 25
cardiac pump failure-related, 25  
cocaine-related, 204  
coronary atherosclerosis-related, 25  
prevention of  
with amiodarone, 196  
with beta-blockers, 193  
with eplerenone, 195  
with implantable cardioverter defibrillator, 197–199  
with valsartan, 198  
racial differences in, 237  
smoking-related, 296  
thrombotic, 29  
Supraventricular tachyarrhythmias, 175  
hemodynamic consequences of, 181  
initial evaluation and treatment of, 182–186  
mechanisms of, 175–176  
paroxysmal, 183  
Supraventricular tachycardia, treatment of, 183, 184  
Surgical management, of acute coronary syndromes, 154–162  
intraaortic balloon counterpulsation (IABP), 158–159  
intraoperative considerations in, 159–160  
off-pump surgery, 160  
preoperative assessment for, 154–155  
revascularization, 67–68, 140, 155–158  
ventricular assist devices and, 160–161  
Syndrome X, 252–253  

T  
Tachycardia. See also specific tachycardias  
cardiac tamponade-related, 149  
cardiogenic shock-related, 132, 136  
narrow QRS complex, 175  
Tamponade, cardiac, 149–151  
aortic dissection-related, 256  
as cardiogenic shock cause, 134, 136–137, 138  
pathophysiology of, 149  
pericardial, 147, 254  
pericardial effusion associated with, 147  
signs and symptoms of, 149–151  
treatment of, 151  
ventricular free wall rupture-related, 109  
Thrombolytic therapy  
for cocaine-related myocardial infarction, 208  
in elderly patients, 217  
as hemopericardium cause, 149  
history of, 3  
hypertension as contraindication to, 266  
as ventricular free wall rupture risk factor, 109  
in women, 217  
Thrombosis  
in acute coronary syndrome  
pathophysiology, 26  
coronary  
early experimental studies of, 1  
as mortality cause, 1  
treatment of, 3  
left ventricular, 101–102  
as myocardial infarction cause, 3  
in non-ST-segment elevation myocardial infarction, 60  
overlying atherosclerotic plaques, 32  
pathophysiology of, 29, 30, 60  
racial factors in, 234–235  
venous  
deep, 260  
as myocardial infarction complication, 2  
Ticlopidine, 65  
TIMI (Thrombolysis in Myocardial Infarction) risk score, 62–63, 76, 77  
Tirofiban, 46, 79–80  
as non-ST-segment elevation myocardial infarction treatment, 65–66, 216  
as unstable angina treatment, 216  
use in women and the elderly, 2166  
Tissue factor, 29, 32  
Tissue-plasminogen activator, 3  
racial differences in response to, 235–236  
Torsade de pointes, azimilide-related, 196  
Transfer, of patients, for percutaneous coronary interventions, 53–54
Trauma, as aortic dissection risk factor, 256
Tricuspid regurgitation, right ventricular infarction-related, 100
Triglyceride levels elevated
as metabolic syndrome component, 213, 231
treatment of, 288
racial differences in, 232
Troponins I and T, 4, 41–42, 44, 62
cocaine-related increase in, 206
as myocarditis treatment, 255
in noncardiac conditions, 42
in non-ST segment elevation myocardial infarction, 63
in ST-segment-elevation myocardial infarction, 55–56
in women, 21
Tuskegee experiment, 239

V
Valsartan, 198
Valvular heart disease, as chest pain cause, 252
Varenicline, 299
Vascular lesions, intracranial, as contraindication to fibrinolytic therapy, 50
Vasoconstriction, in acute coronary syndromes, 29–30
Vasodilatation, coronary, in African Americans, 234
Vasospasm. See also Coronary arteries, spasms of
as impaired arterial blood flow cause, 29
nitrate therapy for, 63
Ventilation-perfusion (V/Q) scans, 260
Ventricular arrhythmias
cocaine-related, 208
life-threatening, 155
post-myocardial infarction, 190–203
accelerated idioventricular rhythm, 190–191
antiarrhythmic drug therapy for, 195–196
implantable cardioverter-defibrillators for, 197–199
lidocaine prophylaxis for, 192
medical therapy for, 193–196
nonsustained ventricular tachycardia, 191
premature ventricular contractions, 190
sustained ventricular tachycardia, 191–192
therapeutic approach to, 192–199
ventricular fibrillation, 191–192
Ventricular assist devices, 160–161
Ventricular fibrillation, after myocardial infarction, 191–192
Ventricular free wall rupture, 109–110
aortic dissection-related, 256
in ST-segment-elevation myocardial infarction, 148–149
Ventricular infarction
left, with right ventricular infarction, 100
right
as cardiogenic shock cause, 134, 136
echocardiographic assessment of, 100–101
with left ventricular infarction, 100
with posterior septal wall rupture, 100
Ventricular septal defects/rupture
as cardiogenic shock cause, 134, 137, 138, 140
echocardiographic assessment of, 100
inferior myocardial infarction-related, 100
Ventricular systole, 253
Ventricular tachyarrhythmia, supraventricular tachyarrhythmia-related, 183
Ventricular tachycardia
nonsustained, 191
sustained, 191–192
treatment of, 1, 193, 194–195
Ventriculography, 138, 154
Verapamil, as atrial fibrillation treatment, 185
Viagra (sildenafil), 267

W
Women, cardiovascular disease/acute coronary syndrome in
aortic dissection, 256
clinical presentation of, 214–215
coronary artery disease, 212
outcome of, 220–221
risk factors for, 212–213
coronary thrombi, 32
hospital-based management and
treatment of, 215–220
as mortality cause, 212
Z
Zofenopril, 194